Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

M. Vališ, A. Achiron, HP. Hartung, J. Mareš, V. Tichá, P. Štourač, S. Halusková, F. Angelucci, Z. Pavelek

. 2023 ; 23 (4) : 331-338. [pub] 20230828

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000511

Grantová podpora
Cooperatio Program Charles University in Prague, Czech Republic
research area NEUR Charles University in Prague, Czech Republic
FN HK 00179906 grant projects of the Ministry of Health of the Czech Republic

Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing-remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scientists are analysing whether patients can switch from fingolimod to siponimod and identifying the advantages or disadvantages of such a switch from a therapeutic point of view. In this review, we aim to discuss the therapeutic effects of these two drugs and the advantages/disadvantages of switching treatment from fingolimod to siponimod in patients with the most common forms of MS, RRMS and SPMS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000511
003      
CZ-PrNML
005      
20240213093226.0
007      
ta
008      
240109s2023 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40268-023-00434-6 $2 doi
035    __
$a (PubMed)37640862
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Vališ, Martin $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05, Hradec Králové, Czech Republic
245    14
$a The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis / $c M. Vališ, A. Achiron, HP. Hartung, J. Mareš, V. Tichá, P. Štourač, S. Halusková, F. Angelucci, Z. Pavelek
520    9_
$a Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing-remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scientists are analysing whether patients can switch from fingolimod to siponimod and identifying the advantages or disadvantages of such a switch from a therapeutic point of view. In this review, we aim to discuss the therapeutic effects of these two drugs and the advantages/disadvantages of switching treatment from fingolimod to siponimod in patients with the most common forms of MS, RRMS and SPMS.
650    _2
$a lidé $7 D006801
650    _2
$a fingolimod hydrochlorid $x škodlivé účinky $7 D000068876
650    12
$a chronicko-progresivní roztroušená skleróza $x farmakoterapie $x chemicky indukované $7 D020528
650    12
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    12
$a neurodegenerativní nemoci $x chemicky indukované $x farmakoterapie $7 D019636
650    _2
$a recidiva $7 D012008
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a imunosupresiva $x škodlivé účinky $7 D007166
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Achiron, Anat $u Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel $u Neurology Department, Sheba Medical Center, Tel-Hashomer, Israel $u Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
700    1_
$a Hartung, Hans Peter $u Department of Neurology, Medical School, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany $u Department of Neurology, Faculty of Medicine at Palacký University and University Hospital in Olomouc, I. P. Pavlova 6, Olomouc, Czech Republic $u Brain and Mind Center, University of Sydney, Sydney, Australia
700    1_
$a Mareš, Jan $u Department of Neurology, Faculty of Medicine at Palacký University and University Hospital in Olomouc, I. P. Pavlova 6, Olomouc, Czech Republic
700    1_
$a Tichá, Veronika $u First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Štourač, Pavel $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05, Hradec Králové, Czech Republic
700    1_
$a Halusková, Simona $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05, Hradec Králové, Czech Republic
700    1_
$a Angelucci, Francesco $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05, Hradec Králové, Czech Republic $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Pavelek, Zbyšek $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05, Hradec Králové, Czech Republic. zbysekpavelek@email.cz $1 https://orcid.org/0000000217728781
773    0_
$w MED00007936 $t Drugs in R&D $x 1179-6901 $g Roč. 23, č. 4 (2023), s. 331-338
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37640862 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093223 $b ABA008
999    __
$a ok $b bmc $g 2049269 $s 1210205
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 23 $c 4 $d 331-338 $e 20230828 $i 1179-6901 $m Drugs in R&D $n Drugs R D $x MED00007936
GRA    __
$a Cooperatio Program $p Charles University in Prague, Czech Republic
GRA    __
$a research area NEUR $p Charles University in Prague, Czech Republic
GRA    __
$a FN HK 00179906 $p grant projects of the Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace